6 ST JOHNS LANE, FLOOR 5, NEW YORK, NY
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Material disclosure
Director Resignations - Anthony D. Eisenberg and Sooyoung Lee Step Down
Abpro Holdings Enters $147,000 Loan Agreement with CEO Miles J.W. Suk
Announce U.S. FDA IND Clearance for Lead Multispecific Antibody Cancer Candidate ABP-102 / CT-P72
Announces Submission of an IND Application to Initiate a Phase 1 Clinical Trial of T Cell Engager ABP-102/CT-P72 for HER2-positive Cancers
Granted Nasdaq Listing Extension to Pursue Compliance and Strategic Objectives
To Present Preclinical Data for CT-P72/ABP-102 at SITC 2025, Highlighting a Next-Generation HER2×CD3 T-Cell Engager
Q1
Notice of Late Filing for Quarterly Report
Amended Annual Report
FY 2025
Notice of Late Filing for Annual Report
Q3
Q2
Effectiveness Notice
Amended Registration Statement for Securities
Prospectus filed pursuant to Rule 424(b)(3)
S-1
Registration Statement for Securities to be Offered to Employees
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
Correspondence
Submission Upload
Post-Effective Amendment to Registration Statement
SEC Staff Correspondence